TODAY: Don't miss the Novavax team at @vaccinenation's World Vaccine Congress 2024. #WVCDC Our Chief Medical Officer, Dr. Bob Walker, will be featured in this morning's keynote panel, titled "The future of COVID-19 vaccinations. Should we be developing broadly protective antigens or combinational vaccines?"  #WVCDC

ICYMI: We recently announced results that expand our knowledge of NVX-CoV2373 and its ability to help protect from COVID19 over a longer period of time. Let's talk about what it means. Thread: Our new data build on findings from our #UK Phase 3 #clinicaltrial (randomized, placebo-controlled, double-blind, with crossover), where we examined vaccine performance in 15K adults. Publication: nejm.org/doi/full/10.10…

Our new data build on findings from our #UK Phase 3 #clinicaltrial (randomized, placebo-controlled, double-blind, with crossover), where we examined vaccine performance in 15K adults. Publication: nejm.org/doi/full/10.10… There, we found an overall vaccine efficacy of 89.7%. A median of 55 days of surveillance was used for the final analysis. The Alpha (B.1.1.7) strain predominated during this time, with 86.3% efficacy vs Alpha.

Today we're thrilled to announce results of our PREVENT-19 Phase 3 pediatric expansion to adolescents (ages 12 through 17). Let's talk about the data and what they mean. Thread: Today's results build on findings from the adult main study, investigating the safety & efficacy of NVX-CoV2373 in the United States and Mexico amidst an evolving #COVID19 pandemic: nejm.org/doi/full/10.10… #clinicaltrials

We're thrilled to announce that PREVENT-19 (US/Mex Phase 3) results were submitted for publication. The manuscript is now available as a pre-print. Let's dive into what we found. Thread: medrxiv.org/content/10.110… PREVENT-19 builds on observations from other/ongoing #clinicaltrials, investigating the safety & efficacy of NVX-CoV2373 in the United States and Mexico amidst an evolving #COVID19 pandemic. ir.novavax.com/2021-08-05-Nov…

We’re proud to announce the publication of our successful Phase 3 trial of NanoFlu™, our seasonal quadrivalent Nanoparticle #Influenza #Vaccine (#qNIV) candidate, in @TheLancetInfDis. Let’s dig into why it matters: thelancet.com/journals/lanin…

Thread: According to @CDC, “on average, about 8% of the U.S. population gets sick from #flu each season.” There is an urgent need for improved flu #vaccines, particularly for older adults (>age 65), who bear higher disease burden. cdc.gov/flu/about/keyf…

NEWS: Novavax Announces #COVID19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination ir.novavax.com/2021-08-05-Nov… Following the primary vaccination series (21 days apart), a single booster dose at 6 months of NVX-CoV2373 induced a robust increase in anti-Spike antibody levels - up ~4.6-fold vs the response seen after the primary series.

NEWS: Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax’ Recombinant Nanoparticle #COVID19 Vaccine ir.novavax.com/2021-08-05-Nov… The submissions were made to the Drugs Controller General of India (DCGI) and regulatory agencies in Indonesia and the Philippines.

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial bit.ly/2MyjKwC First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants.